More Articles

Access and Evidence

Pragmatic Trials: RWE’s Hidden Gem

Ross Davies, (Jun 20, 2018)

Pragmatic trials continue to be overlooked in the RWE space – particularly in the US. Can we expect to see wider stateside adoption?

The Big Trends Transforming Pharma

Adam Chapman, (Jun 15, 2018)

The industry is fast approaching a promising new future. How is it getting there?
Patients and Medical

The Power Of Empathy

Adam Chapman, (Jun 12, 2018)

In a bid to better understand and engage patients, pharma companies are becoming as compassionate as they are scientific.

Artificial Intelligence: The Counter-Argument

Adam Chapman, (Jun 7, 2018)

AI is being touted as the doctor’s new lifeline — we put this proposition to a skeptical doctor.

Sizing Up Pharma’s Tech Maturity

Andy stone, (Jun 1, 2018)

Amateurs or aficionados? We get an expert appraisal of the industry’s tech proficiency
Access and Evidence

The Naked Truth About Outcomes-Based Pricing

Ross Davies, (May 22, 2018)

Hype around outcomes-based contracts has been doing the rounds for some time now, but is pharma delivering the goods?
Patients and Medical

Pharma, Stop Flummoxing Patients

Danielle Barron, (May 15, 2018)

Efforts to empower patients are undermined by bamboozling medical information. Is there a straight-forward solution?

Leadership In Japan

Ross Davies, (May 11, 2018)

In the face of new drug pricing reforms, the need to nurture strong leadership is imperative, but not without its challenges.

How To Attract Investors

Ross Davies, (May 4, 2018)

The precarious climate in the US might have spooked some pharma investors – but others are looking to targeted therapies to get more bang for their buck.

How Well Do You Know Your HCP?

Adam Chapman, (May 3, 2018)

Machine learning is a boon for customer engagement. How can pharma best use it?